Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Dennis Heaney

Psychiatry Edmond, OK Physician Assistant

NPI 1437868254 CMS profile 11391110

2000 Sonoma Park Dr, Edmond, OK 73013

Open in the dashboard

General payments

$12,011

694 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dennis Heaney of Edmond, OK is reported in the CMS Open Payments database as having received $12,011 across 694 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,755 221
2024 General $3,738 254
2023 General $4,212 204
2022 General $307 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dennis Heaney
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Dennis Heaney were reported at $3,755. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Dennis Heaney Psychiatry median Middle half National median
2019 $0 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $307 $153 $50–$590 $149
2023 $4,212 $170 $56–$651 $160
2024 $3,738 $179 $57–$673 $164
2025 $3,755 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $1,461 93 payments
  2. ITI, Inc. $1,352 63 payments
  3. Axsome Therapeutics, Inc. $1,034 68 payments
  4. Alkermes, Inc. $826 53 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $789 32 payments
  6. Noven Therapeutics, LLC $757 60 payments
  7. Neurocrine Biosciences, Inc. $740 52 payments
  8. Janssen Pharmaceuticals, Inc $737 33 payments
  9. Otsuka America Pharmaceutical, Inc. $714 54 payments
  10. Ironshore Pharmaceuticals Inc. $593 30 payments
  11. Other $3,009 156 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $11,905 693 payments
  2. Education $106 1 payment
Products named General payments · program years 2022–2025
  1. VRAYLAR $1,132 65 payments
  2. CAPLYTA $921 42 payments
  3. TRINTELLIX $789 32 payments
  4. LYBALVI $774 49 payments
  5. INGREZZA $740 52 payments
  6. SPRAVATO $737 33 payments
  7. Xelstrym $717 58 payments
  8. Auvelity $690 49 payments
  9. REXULTI $681 52 payments
  10. JORNAY PM $558 28 payments
  11. Other $7,744 464 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

164

Median for Psychiatry & Neurology: 100

Drug cost

$10,520

Median for Psychiatry & Neurology: $2,986

Branded share of claims

27.4%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belsomra Suvorexant Brand 12 $5,286
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 20 $2,902
Bupropion Xl Bupropion Hcl Brand 13 $721
Aripiprazole Generic 11 $412
Lamotrigine Generic 15 $258
Gabapentin Generic 15 $245
Pregabalin Generic 23 $241
Olanzapine Generic 14 $230
Trazodone Hcl Generic 14 $168
Alprazolam Generic 27 $58

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $261
  • Otsuka America Pharmaceutical, Inc. $214
$475 — —
VRAYLAR
  • AbbVie, Inc. $470
$470 — —
CAPLYTA
  • ITI, Inc. $395
$395 — —
Auvelity
  • Axsome Therapeutics, Inc. $285
$285 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $237
$237 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

694 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record